JP2001515493A - 改変された親和性を有するアデノウイルスベクター - Google Patents

改変された親和性を有するアデノウイルスベクター

Info

Publication number
JP2001515493A
JP2001515493A JP53984898A JP53984898A JP2001515493A JP 2001515493 A JP2001515493 A JP 2001515493A JP 53984898 A JP53984898 A JP 53984898A JP 53984898 A JP53984898 A JP 53984898A JP 2001515493 A JP2001515493 A JP 2001515493A
Authority
JP
Japan
Prior art keywords
fgf
receptor
vector
cells
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP53984898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515493A5 (https=
Inventor
エイ． ソスノウスキ，バーバラ
バード，アンドリュー
エフ． ピアース，グレン
ティー． キュリエル，デイビッド
ティー． ダグラス，ジョアン
イー． ロジャーズ，バック
Original Assignee
セレクティブ ジェネティックス，インコーポレイテッド
ユーエイビー リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレクティブ ジェネティックス，インコーポレイテッド, ユーエイビー リサーチ ファウンデーション filed Critical セレクティブ ジェネティックス，インコーポレイテッド
Publication of JP2001515493A publication Critical patent/JP2001515493A/ja
Publication of JP2001515493A5 publication Critical patent/JP2001515493A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
JP53984898A 1997-03-14 1998-03-13 改変された親和性を有するアデノウイルスベクター Ceased JP2001515493A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4078297P 1997-03-14 1997-03-14
US60/040,782 1997-03-14
US6526597P 1997-11-10 1997-11-10
US60/065,265 1997-11-10
PCT/US1998/004964 WO1998040508A1 (en) 1997-03-14 1998-03-13 Adenoviral vectors with modified tropism

Publications (2)

Publication Number Publication Date
JP2001515493A true JP2001515493A (ja) 2001-09-18
JP2001515493A5 JP2001515493A5 (https=) 2005-11-10

Family

ID=26717429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53984898A Ceased JP2001515493A (ja) 1997-03-14 1998-03-13 改変された親和性を有するアデノウイルスベクター

Country Status (6)

Country Link
US (2) US6613563B1 (https=)
EP (1) EP0973926A1 (https=)
JP (1) JP2001515493A (https=)
AU (1) AU742365B2 (https=)
CA (1) CA2283461A1 (https=)
WO (1) WO1998040508A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504274A (ja) * 2003-05-10 2007-03-01 ペン、ジャオフイ 増殖性疾患を治療するためのアデノウイルスベクターとｐ５３遺伝子との組換え体遺伝子医薬
US7858356B2 (en) 2005-11-24 2010-12-28 Genomidea, Inc. Mutant paramyxovirus and method for production thereof

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010006629A1 (en) * 1993-10-25 2001-07-05 Richard J. Gregory Recombinant adenoviral vector and methods of use
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US20060275261A1 (en) * 1993-10-25 2006-12-07 Canji, Inc. Adenoviral vectors having a protein IX deletion
EP1637608B1 (en) * 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
US7060433B1 (en) 1999-11-12 2006-06-13 Rigel Pharmaceuticals, Inc. Methods and compositions for screening using diphtheria toxin constructs
DE19845434C1 (de) * 1998-10-02 2000-03-16 Juergen Schrader Gewebebindende Peptide, ihre Identifizierung, Herstellung und Verwendung
JP5448283B2 (ja) * 1998-11-19 2014-03-19 ジョージタウン・ユニバーシティ 全身性ウイルス／リガンド遺伝子送達システムおよび遺伝子治療
DK2385124T3 (da) 1999-05-14 2013-11-18 Arbor Vita Corp Peptider, eller peptid-analoger, til modulering af bindingen af et PDZ protein og et PL protein
EP1223952B1 (en) * 1999-10-07 2008-04-16 Carlos Estuardo Aguilar-Cordova Methods for treatment of solid tumors and metastasis by gene therapy
WO2001026643A1 (en) * 1999-10-14 2001-04-19 The Wistar Institute Inhibition of tumorigenic properties of melanoma cells
AU2001234981A1 (en) 2000-02-09 2001-08-20 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
WO2001066148A1 (en) * 2000-03-08 2001-09-13 Neurosearch A/S A method of sensitising endothelial cells to prodrugs
CA2414272A1 (en) * 2000-07-10 2002-01-17 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US6506365B1 (en) * 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
CN1520303B (zh) * 2001-03-27 2013-04-24 纽约大学 利用基于α病毒且靶向高亲和性层粘连蛋白受体的载体进行肿瘤治疗
US20050043227A1 (en) * 2001-04-24 2005-02-24 Veerle Compernolle Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
JP2002335965A (ja) * 2001-05-14 2002-11-26 Japan Science & Technology Corp 細胞特異的発現複製ベクター
EP1399023B1 (en) * 2001-06-01 2008-04-30 Wyeth COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENETIC PROTEINS& x9;
WO2002103004A1 (en) * 2001-06-15 2002-12-27 The Children's Hospital Of Philadelphia Surface modification for improving biocompatibility
KR101072867B1 (ko) * 2001-10-31 2011-10-17 유니버시티 오브 노스 텍사스 헬스 사이언스 센터 뼈 형태발생 단백질(ｂｍｐ), ｂｍｐ 수용체 및 ｂｍｐ 결합 단백질 및 녹내장 진단 및 치료에서 그의 용도
US20030133912A1 (en) * 2001-12-11 2003-07-17 Davidson Beverly L. Receptor-targeted adenoviral vectors
FR2842823A1 (fr) * 2002-07-25 2004-01-30 Inst Nat Sante Rech Med Adenovirus modifies pour le ciblage des lymphocytes b
US7033333B1 (en) * 2002-08-02 2006-04-25 Arthur Croft Self actuated cervical (neck) traction device
WO2004029581A2 (en) * 2002-09-26 2004-04-08 The Children's Hospital Of Philadelphia Method of determining surface binding capacity
US20070098702A1 (en) * 2005-02-17 2007-05-03 University Of Maryland, Baltimore Recombinant protein polymer vectors for systemic gene delivery
WO2007050128A2 (en) * 2005-05-31 2007-05-03 Vectorlogics, Inc. Shielded adenoviral vectors and methods of use
US20100150885A1 (en) * 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7659999B2 (en) * 2005-12-23 2010-02-09 Xerox Corporation UIdesign: N-up calculator user interface
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc BIO-HETERODUPLEX TRACKING TEST
WO2008128251A1 (en) * 2007-04-17 2008-10-23 The Children's Hospital Of Philadelphia Humanized viral vectors and methods of use thereof
JP5763525B2 (ja) * 2008-05-07 2015-08-12 サーモディクス，インコーポレイティド 粒子からの核酸複合体の送達
US20110159098A1 (en) * 2009-12-30 2011-06-30 Surmodics, Inc. Stabilization and delivery of nucleic acid complexes
WO2011127340A2 (en) * 2010-04-08 2011-10-13 University Of Florida Research Foundation, Inc. Viral-based transient-expression vector system that allows multiple applications
US8389804B2 (en) 2010-04-08 2013-03-05 University Of Florida Research Foundation, Inc. Viral based transient-expression vector system that allows multiple applications
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
RU2542385C2 (ru) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
US10947282B2 (en) 2015-01-19 2021-03-16 The Texas A & M University System Functionalized protein-based materials and their uses
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
WO2018213235A1 (en) 2017-05-16 2018-11-22 Life Technologies Corporation Methods for compression of molecular tagged nucleic acid sequence data
US20220340627A1 (en) * 2019-09-20 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Dach1 builds artery networks that protect against cardiac injury in adults

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5191067A (en) * 1989-04-27 1993-03-02 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
FR2649119A1 (fr) * 1989-06-30 1991-01-04 Centre Nat Rech Scient Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels
CA2098849C (en) * 1990-12-20 2007-07-10 Dana-Farber Cancer Institute Control of gene expression by ionizing radiation
ATE245703T1 (de) * 1992-09-22 2003-08-15 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
BR9406715A (pt) * 1993-05-12 1996-02-06 Genetics Inst Molécula de DNA isolada célula hospedeira vetor método para produzir uma proteina (BMP-11) polipeptideo de proteina-11 morfogenética de osso purificada (BMP-11) e molécula de DNA quimérica
US6312699B1 (en) * 1994-03-28 2001-11-06 Uab Research Foundation Ligands added to adenovirus fiber
JPH11510050A (ja) 1995-07-25 1999-09-07 イントロヘーネ ベスローテン フェンノートシャップ 標的遺伝子送達のための方法および手段

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504274A (ja) * 2003-05-10 2007-03-01 ペン、ジャオフイ 増殖性疾患を治療するためのアデノウイルスベクターとｐ５３遺伝子との組換え体遺伝子医薬
US7858356B2 (en) 2005-11-24 2010-12-28 Genomidea, Inc. Mutant paramyxovirus and method for production thereof

Also Published As

Publication number Publication date
CA2283461A1 (en) 1998-09-17
AU6462998A (en) 1998-09-29
US20040029280A1 (en) 2004-02-12
WO1998040508A1 (en) 1998-09-17
EP0973926A1 (en) 2000-01-26
AU742365B2 (en) 2002-01-03
US6613563B1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
JP2001515493A (ja) 改変された親和性を有するアデノウイルスベクター
RU2209088C2 (ru) Опосредованная рецепторами доставка генов с использованием векторов на основе бактериофагов
AU773202B2 (en) Targeted adenovirus vectors for delivery of heterologous genes
JP2001503250A (ja) 束縛ペプチドモチーフを用いたターゲッティングアデノウイルス
JP2000516098A (ja) 短シャフトアデノウイルスファイバーおよびその用途
JP2002513290A (ja) 修飾されたファイバー蛋白質を有するアデノウイルスによる遺伝子移入
US20040071660A1 (en) Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts
JP2004502450A (ja) ターゲッティング遺伝子送達のための二官能性分子およびそれと複合化されたベクター
WO2000067576A1 (en) Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
US20040175362A1 (en) Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
JP2001521387A (ja) アポトーシス誘発タンパク質ｖｐ２および／またはアポプチンを発現する遺伝子伝達体
JP2007535900A (ja) キメラアデノウイルスキャプシドタンパク質
FR2860004A1 (fr) Nouveau vecteur adenoviral pour l'infection de cellules deficientes ou depourvues en recepteurs car
AU771686B2 (en) Adenoviral vectors with modified tropism
MXPA98004203A (en) Vectors and methods for gene transfer acelu
HK1002284B (en) Novel implant and novel vector for the treatment of acquired diseases
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
MXPA00002076A (en) Receptor-mediated gene delivery using bacteriophage vectors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080925

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080925

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20090526

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20100406

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20100415

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20100513

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100601